在病毒抑制下治疗HBV补偿性肝硬化患者的卡维迪洛尔加NUC:随机开放试验
Bingqiong Wang1, Jialing Zhou1, Xiaoning Wu1
1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China.
在B型肝炎病毒 (HBV) 相关的肝硬化患者中,添加卡维迪醇到核胺类同类 (NUC) 治疗并没有显著延迟食道静脉 (EV) 进展. 然而,卡维迪醇对中等EV回归显示出潜在的益处.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 门高血压是肝硬化的一种并发症.
- 食道静脉 (EV) 是门高血压的常见后果.
- 贝塔抑制剂在控制乙型肝炎病毒 (HBV) 相关肝硬化病的EV进展中的作用需要进一步调查.
研究的目的:
- 评估添加卡维迪洛尔添加到抗HBV治疗中,以延缓HBV补偿性肝硬化中EV进展的疗效.
- 为了评估卡维迪醇对EV回归的影响,在患有中小型静脉动脉的患者中.
主要方法:
- 一项随机对照试验,涉及HBV补偿性肝硬化和小/中等EV的患者.
- 参与者接受了单独的核化类似物 (NUC) 或NUC加卡维迪醇 (12.5毫克).
- 主要终点是2年随访期间的EV进展率.
主要成果:
- 在NUC单独治疗和卡维迪洛结合组之间,EV进展率没有统计学上显著的差异 (15.5%对12.7%,P=0.567).
- 卡维迪醇组合组显示,中等大小的静脉动脉 (43.5%对13.1%,P=0.022) 的EV回归显著增加,但小的静脉动脉则没有.
- 肝脏相关事件的发生率在两组之间是相似的.
结论:
- 在NUC治疗中添加carvedilol并没有显著地阻止HBV相关肝硬化病的EV进展.
- 卡维迪洛尔可能有助于促进中型食道静脉的回归.
- 进一步的研究可能会澄清卡维迪醇在这种患者群体中管理EV的特定作用.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Mitral Stenosis III: Medical Management
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


